Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo

Bone

Volumn 22, Issue 5, 1998, Pages 455-461

  Giuliani, N ^a   Pedrazzoni, M ^a   Negri, G ^a   Passeri, G ^a   Impicciatore, M ^a   Girasole, G ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Alendronate; Bisphosphonates; Bone formation; Bone marrow; Etidronate; Fibroblast colony forming units

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DEXAMETHASONE; ETIDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CULTURE; COLONY FORMING UNIT; COLONY FORMING UNIT F; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; MINERALIZATION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRECURSOR; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

AGE FACTORS; ANIMALS; BONE MARROW CELLS; CALCIFICATION, PHYSIOLOGIC; CELL DIVISION; CELLS, CULTURED; CLODRONIC ACID; COLONY-FORMING UNITS ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; ETIDRONIC ACID; FEMALE; FIBROBLASTS; HUMANS; INJECTIONS, SUBCUTANEOUS; MICE; OSTEOBLASTS;

EID: 0031979896     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(98)00033-7     Document Type: Article

References (37)

1. Adami, S., Passeri, M., Ortolani, S., Broggini, M., Carratelli, L., Caruso, I., Gandolini, G., Gnessi, L., Laurenzi, M., Lombardi, A., Norbiato, G., Pryor-Tillotson, S., Reda, C., Romanini, L., Subrizi, D., Wei, L., and Yates, A. J. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 17:383-390; 1995.
2. Adamson, B. B., Gallacher, S. J., Byars, J., Ralston, S. H., Boyle, I. T., and Boyce, B. F. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 342:1459-1460; 1993.
3. Balena, R., Toolan, B. C., Shea, M., Markatos, A., Myers, E. R., Lee, S. C., Opas, E. E., Seedor, J. G., Klein, H., Frankenfield, D., Quartuccio, H., Fioravanti, C., Clair, J., Brown, E., Hayes, W. C., and Rodan, G. A. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92:2577-2586; 1993.
4. Brunner, G., Nguyen, H., Gabrilove, J., Rifkin, D. B., and Wilson, E. L. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood 81:631-638; 1993.
5. Canalis, E., Centrella, M., and McCarthy, T. Effects of basic fibroblast growth factor on bone formation in vitro. J Clin Invest 81:1572-1577; 1988.
6. Carano, A., Teitelbaum, S. L., Konsek, J. D., Schlesinger, P. H., and Blair, H. C. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85:456-461; 1990.
7. Cheng, S. L., Yang, J. W., Rifas, L., Zhang, S. F., and Avioli, L. V. Differentiation of human bone marrow osteogenic stromal cells in vitro: Induction of the osteoblast phenotype by dexamethasone. Endocrinology 134: 277-286; 1994.
8. Endo, N., Rutledge, S. J., Opas, E. E., Vogel, R., Rodan, G. A., and Schmidt, A. Human protein tyrosine phosphatase-sigma: Alternative splicing and inhibition by bisphosphonates. J Bone Miner Res 11:535-543; 1996.
9. Fleisch, H., Russell, R. G., and Francis, M. D. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262-1264; 1969.
10. Giannini, S., D'Angelo, A., Malvasi, L., Castrignano, R., Pati, T., Tronca, R., Liberto, L., Nobile, M., and Crepaldi, G. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 14:137-141; 1993.
11. Giuliani, N., Girasole, G., Pedrazzoni, M., Passeri, G., Gatti, C., and Passeri, M. Alendronate stimulate b-FGF production and mineralized nodule formation in human osteoblastic cells and osteoblastogenesis in human bone marrow cultures. J Bone Miner Res 10(Suppl):S171; 1995.
12. Guenther, H. L., Guenther, H. E., and Fleisch, H. The effects of 1-hydroxyethane-1, 1-diphosphonate and dichloromethanediphosphonate on collagen synthesis by rabbit articular chondrocytes and rat bone cells. Biochem J 196:293-301; 1981.
13. Haynesworth, S. E., Goshima, J., Goldberg, V. M., and Caplan, A. I. Characterization of cells with osteogenic potential from human marrow. Bone 13:81-88; 1992.
14. Jilka, R. L., Weinstein, R. S., Takahashi, K., Parfitt, A. M., and Manolagas, S. C. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest 97:1732-1740; 1996.
15. Khairi, M. R., Altman, R. D., DeRosa, G. P., Zimmermann, J., Schenk, R. K., and Johnston, C. C. Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. Ann Intern Med 87:656-663; 1977.
16. Khokher, M. A. and Dandona, P. Diphosphonates inhibit human osteoblast secretion and proliferation. Metabolism 38:184-187; 1989.
17. Landman, J. O., Hamdy, N. A. T., Pauwels, E. K. J., and Papapoulos, S. E. Skeletal metabolism in patients with osteoporosis after discontinuation of long term treatment with oral pamidronate. J Clin Endocrinol Metab 80:3465-3468; 1995.
18. Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Jr., Dequeker, J., Favus, M., Seeman, E., Recker, R. R., Capizzi, T., Santora, A. C., II, Lombardi, A., Shah, R. V., Hirsch, L. J., and Karpf, D. B. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443; 1995.
19. Lin, J. H. Bisphosphonates: A review of their pharmacokinetic properties. Bone 18:75-85; 1996.
20. Lin, J. H., Duggan, D. E., Chen, I. W., and Ellsworth, R. L. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos Biol Fate Chem 19:926-932; 1991.
21. Long, M. W., Robinson, J. A., Ashcraft, E. A., and Mann, K. G. Regulation of human bone marrow-derived osteoprogenitor cells by osteogenic growth factors. J Clin Invest 95:881-887; 1995.
22. Nishikawa, M., Akatsu, T., Katayama, Y., Yasutomo, Y., Kado, S., Kugai, N., Yamamoto, M., and Nagata, N. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18:9-14; 1996.
23. Noff, D., Pitaru, S., and Savion, N. Basic fibroblast growth factor enhances the capacity of bone marrow cells to form bone-like nodules in vitro. FEBS Lett 250:619-621; 1989.
24. Owen, M. and Friedenstein, A. J. Stromal stem cells: Marrow-derived osteogenic precursors. Ciba Found Symp 136:42-60; 1988.
25. Passeri, M., Baroni, M. C., Pedrazzoni, M., Pioli, G., Barbagallo, M., Costi, D., Biondi, M., Girasole, G., Arlunno, B., and Palummeri, E. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-l, 1-bisphosphonate (AH-BuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 15:237-247; 1991.
26. Rodan, G. A. and Fleisch, H. A. Bisphosphonates: Mechanisms of action. J Clin Invest 97:2692-2696; 1996.
27. Rossini, M., Gatti, D., Zamberlan, N., Braga, V., Dorizzi, R., and Adami, S. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 9:1833-1837; 1994.
28. Sahni, M., Guenther, H. L., Fleisch, H., Collin, P., and Martin, T. J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004-2011; 1993.
29. Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., and Rodan, G. A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105; 1991.
30. Savion, N., Pri-Chen, S., and Pitaru, S. bFGF enhances the growth and the expressions of the osteogenic phenotype of dexametasone trated human bone marrow derived bone-like cells in culture. J Bone Miner Res 11(Suppl):S176; 1996.
31. Shinoda, H., Adamek, G., Felix, R., Fleisch, H., Schenk, R., and Hagan, P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 35:87-99; 1983.
32. Storm, T., Steiniche, T., Thamsborg, G., and Melsen, F. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 8:199-208; 1993.
33. Tenenbaum, H. C., Torontali, M., and Sukhu, B. Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone 13:249-255; 1992.
34. Toolan, B. C., Shea, M., Myers, E. R., Borchers, R. E., Seedor, J. G., Quartuccio, H., Rodan, G., and Hayes, W. C. Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res 7:1399-1406; 1992.
35. Tsuchimoto, M., Azuma, Y., Higuchi, O., Sugimoto, I., Hirata, N., Kiyoki, M., and Yamamoto, I. Alendronate modulates osteogenesis of human osteoblastic cells in vitro. Jpn J Pharmacol 66:25-33; 1994.
36. Wang, Q. R., Yan, Z. J., and Wolf, N. S. Dissecting the hematopoietic microenvironment. VI. The effects of several growth factors on the in vitro growth of murine bone marrow CFU-F. Exp Hematol 18:341-347; 1990.
37. Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P., Woodson, G. C., and Yanover, M. J. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79; 1990.